Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts.

Summary

The study defines an immune evasion axis in fibrotic lungs: senescent fibroblasts express HLA-E that engages NKG2A on NK cells, suppressing cytotoxicity. Blocking this checkpoint or enhancing NK activity restored killing of senescent fibroblasts in mechanistic models, suggesting an NK-based immunotherapy strategy to reverse fibrosis.

Key Findings

• NKG2A is the predominant inhibitory checkpoint on NK cells in fibrotic lung diseases by scRNA-seq and spectral flow cytometry.
• Senescent fibroblasts express HLA-E, suppressing NK cytotoxicity via NKG2A engagement in coculture assays.
• IPF lung scRNA-seq identified selective HLA-E expression in senescent HAS1-associated fibroblast subsets, linking senescence to immune evasion.

Clinical Implications

Provides a mechanistic rationale to test NKG2A blockade or NK cell–based therapies in fibrotic ILDs such as IPF, potentially complementing or surpassing antifibrotics.

Limitations

• Preclinical/mechanistic focus; in vivo efficacy and safety of NKG2A-targeted therapy in fibrotic lung disease remain to be established.
• Abstract truncation precludes full details on therapeutic experiments or clinical translation.

Future Directions

Translate findings into early-phase trials of NKG2A blockade and/or adoptive NK therapies in IPF, with biomarkers (HLA-E, senescence signatures) for enrichment.